Biotech Values

[DewDiligence]

>I'm thinking about maybe buying some GTCB. The antithrombotic market is small and the competition is increasing, but the market is also growing, and GTCB’s technology is interesting.<

GTC is primarily a technology-platform company. Although the ATryn market in the U.S., especially, figures to be a nice moneymaker, most of what you are investing in (if you do invest) is GTC’s proprietary technology.

Moreover, ATryn is not really part of the general antithrombotic market and is not directly affected by the increasing competition there. Regards, Dew